{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:06:28Z","timestamp":1773885988661,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T00:00:00Z","timestamp":1508198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T00:00:00Z","timestamp":1508198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Our recent findings strongly support the idea of PLAC1 being as a potential immunotherapeutic target in prostate cancer (PCa). Here, we have generated and evaluated an anti-placenta-specific1 (PLAC1)-based antibody drug conjugate (ADC) for targeted immunotherapy of PCa. Prostate cancer cells express considerable levels of PLAC1. The Anti-PLAC1 clone, 2H12C12, showed high reactivity with recombinant PLAC1 and selectivity recognized PLAC1 in prostate cancer cells but not in LS180 cells, the negative control. PLAC1 binding induced rapid internalization of the antibody within a few minutes which reached to about 50% after 15\u2009min and almost completed within an hour. After SN38 conjugation to antibody, a drug-antibody ratio (DAR) of about 5.5 was achieved without apparent negative effect on antibody affinity to cell surface antigen. The ADC retained intrinsic antibody activity and showed enhanced and selective cytotoxicity with an IC50 of 62\u2009nM which was about 15-fold lower compared to free drug. Anti-PLAC1-ADC induced apoptosis in human primary prostate cancer cells and prostate cell lines. No apparent cytotoxic effect was observed in <jats:italic>in vivo<\/jats:italic> animal safety experiments. Our newly developed anti-PLAC1-based ADCs might pave the way for a reliable, efficient, and novel immunotherapeutic modality for patients with PCa.<\/jats:p>","DOI":"10.1038\/s41598-017-13682-9","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T13:40:42Z","timestamp":1507729242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy"],"prefix":"10.1038","volume":"7","author":[{"given":"Mohammad-Reza","family":"Nejadmoghaddam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir-Hassan","family":"Zarnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Ghahremanzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roya","family":"Ghods","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jafar","family":"Mahmoudian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahboobeh","family":"Nazari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Hossein","family":"Ghahremani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Abolhasani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Anissian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2575-9684","authenticated-orcid":false,"given":"Morteza","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rassoul","family":"Dinarvand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,17]]},"reference":[{"key":"13682_CR1","first-page":"7","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA: a cancer journal for clinicians \n66, 7\u201330 (2016).","journal-title":"CA: a cancer journal for clinicians"},{"key":"13682_CR2","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00262-006-0165-3","volume":"55","author":"PM Alves","year":"2006","unstructured":"Alves, P. M. et al. STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. Cancer Immunology, Immunotherapy \n55, 1515\u20131523 (2006).","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"13682_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1476-5381.2012.02138.x","volume":"168","author":"CA Boswell","year":"2013","unstructured":"Boswell, C. A. et al. An integrated approach to identify normal tissue expression of targets for antibody\u2010drug conjugates: case study of TENB2. British journal of pharmacology \n168, 445\u2013457 (2013).","journal-title":"British journal of pharmacology"},{"key":"13682_CR4","doi-asserted-by":"publisher","first-page":"10946","DOI":"10.1158\/0008-5472.CAN-05-2018","volume":"65","author":"AT Collins","year":"2005","unstructured":"Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J. & Maitland, N. J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer research \n65, 10946\u201310951 (2005).","journal-title":"Cancer research"},{"key":"13682_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/path.2478","volume":"217","author":"SH Lang","year":"2009","unstructured":"Lang, S. H., Frame, F. M. & Collins, A. T. Prostate cancer stem cells. The Journal of pathology \n217, 299\u2013306 (2009).","journal-title":"The Journal of pathology"},{"key":"13682_CR6","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/sj.onc.1209327","volume":"25","author":"L Patrawala","year":"2006","unstructured":"Patrawala, L. et al. Highly purified CD44&plus; prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene \n25, 1696\u20131708 (2006).","journal-title":"Oncogene"},{"key":"13682_CR7","doi-asserted-by":"publisher","first-page":"6796","DOI":"10.1158\/0008-5472.CAN-07-0490","volume":"67","author":"L Patrawala","year":"2007","unstructured":"Patrawala, L., Calhoun-Davis, T., Schneider-Broussard, R. & Tang, D. G. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+ \u03b12\u03b21+ cell population is enriched in tumor-initiating cells. Cancer research \n67, 6796\u20136805 (2007).","journal-title":"Cancer research"},{"key":"13682_CR8","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00262-014-1594-z","volume":"63","author":"R Ghods","year":"2014","unstructured":"Ghods, R. et al. High placenta-specific 1\/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma. Cancer Immunology, Immunotherapy \n63, 1319\u20131327 (2014a).","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"13682_CR9","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.eururo.2009.01.015","volume":"57","author":"MJ Pfeiffer","year":"2010","unstructured":"Pfeiffer, M. J. & Schalken, J. A. Stem cell characteristics in prostate cancer cell lines. European urology \n57, 246\u2013255 (2010).","journal-title":"European urology"},{"key":"13682_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/bab.1177","volume":"61","author":"R Ghods","year":"2014","unstructured":"Ghods, R. et al. Immunohistochemical characterization of novel murine monoclonal antibodies against human placenta-specific 1. Biotechnology and Applied Biochemistry \n61, 363\u2013369 (2014b).","journal-title":"Biotechnology and Applied Biochemistry"},{"key":"13682_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-11-107","volume":"11","author":"X Wang","year":"2014","unstructured":"Wang, X., Baddoo, M. C. & Yin, Q. The placental specific gene, PLAC1, is induced by the Epstein-Barr virus and is expressed in human tumor cells. Virology journal \n11, 107 (2014).","journal-title":"Virology journal"},{"key":"13682_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/pd.2506","volume":"30","author":"M Fant","year":"2010","unstructured":"Fant, M., Farina, A., Nagaraja, R. & Schlessinger, D. PLAC1 (Placenta-specific 1): a novel, X-linked gene with roles in reproductive and cancer biology. Prenatal Diagnosis \n30, 497\u2013502 (2010).","journal-title":"Prenatal Diagnosis"},{"key":"13682_CR13","unstructured":"Barea Rold\u00e1n, D. Functional characterization of the placenta specific protein PLAC1 and its use for cancer immunotherapy. http:\/\/ubm.opus.hbz-nrw.de\/volltexte\/2014\/3879\/ (2014)."},{"key":"13682_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1021\/ar700108g","volume":"41","author":"RVJ Chari","year":"2008","unstructured":"Nejadmoghaddam, M.-R., Babamahmoodi, A., Minai-Tehrani, A., Zarnani, A.-H. & Dinarvand, R. The use of objective oriented project planning tools for nanosafety and health concerns: a case study in nanomedicine research project. European Journal of Nanomedicine \n8, 225\u2013231 (2016).","journal-title":"Accounts of chemical research"},{"key":"13682_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1515\/ejnm-2015-0050","volume":"8","author":"M-R Nejadmoghaddam","year":"2016","unstructured":"Venditto, V. J. & Szoka Jr., F. C. Cancer nanomedicines: so many papers and so few drugs! Advanced drug delivery reviews \n65, 80\u201388 (2013).","journal-title":"European Journal of Nanomedicine"},{"key":"13682_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.addr.2012.09.038","volume":"65","author":"VJ Venditto Jr.","year":"2013","unstructured":"Chari, R. V. J. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Accounts of chemical research \n41, 98\u2013107 (2008).","journal-title":"Advanced drug delivery reviews"},{"key":"13682_CR17","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.addr.2013.08.012","volume":"65","author":"R Van der Meel","year":"2013","unstructured":"Van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G. & Van Gaal, E. V. B. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Advanced drug delivery reviews \n65, 1284\u20131298 (2013).","journal-title":"Advanced drug delivery reviews"},{"key":"13682_CR18","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1021\/acsmedchemlett.6b00312","volume":"7","author":"RVJ Chari","year":"2016","unstructured":"Chari, R. V. J. Expanding the Reach of Antibody-Drug Conjugates. ACS Medicinal Chemistry Letters \n7, 974\u2013976 (2016).","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"13682_CR19","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1021\/jm800719t","volume":"51","author":"S-J Moon","year":"2008","unstructured":"Moon, S.-J. et al. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. Journal of Medicinal Chemistry \n51, 6916\u20136926 (2008).","journal-title":"Journal of Medicinal Chemistry"},{"key":"13682_CR20","doi-asserted-by":"publisher","first-page":"9528","DOI":"10.1158\/0008-5472.CAN-07-1350","volume":"67","author":"M Koslowski","year":"2007","unstructured":"Koslowski, M. et al. A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. Cancer research \n67, 9528\u20139534 (2007).","journal-title":"Cancer research"},{"key":"13682_CR21","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","volume":"26","author":"TM Cardillo","year":"2015","unstructured":"Cardillo, T. M. et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2\/SN-38 antibody-drug conjugate: Characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjugate Chemistry \n26, 919\u2013931 (2015).","journal-title":"Bioconjugate Chemistry"},{"key":"13682_CR22","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","volume":"17","author":"TM Cardillo","year":"2011","unstructured":"Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P. & Goldenberg, D. M. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clinical Cancer Research \n17, 3157\u20133169 (2011).","journal-title":"Clinical Cancer Research"},{"key":"13682_CR23","doi-asserted-by":"crossref","unstructured":"Panowski, S., Bhakta, S., Raab, H., Polakis, P. & Junutula, J. R. In MAbs 34\u201345 (Taylor & Francis, 2014).","DOI":"10.4161\/mabs.27022"},{"key":"13682_CR24","volume":"7","author":"AA Bayat","year":"2015","unstructured":"Bayat, A. A. et al. Production and characterization of monoclonal antibodies against human prostate specific antigen. Avicenna journal of medical biotechnology \n7, 2 (2015).","journal-title":"Avicenna journal of medical biotechnology"},{"key":"13682_CR25","doi-asserted-by":"crossref","unstructured":"Xiao, Z., Jackson, D. & Tice, D. A. In Antibody-Drug Conjugates and Immunotoxins 241\u2013253 (Springer, 2013).","DOI":"10.1007\/978-1-4614-5456-4_14"},{"key":"13682_CR26","first-page":"124","volume":"38","author":"J Chen","year":"2006","unstructured":"Chen, J. et al. PLAC1\/CP1 gene expression and autologous humoral immunity in gastric cancer patients. Beijing da xue xue bao. Yi xue ban\u2009=\u2009Journal of Peking University. Health sciences \n38, 124\u2013127 (2006).","journal-title":"Yi xue ban\u2009=\u2009Journal of Peking University. Health sciences"},{"key":"13682_CR27","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1002\/ijc.23341","volume":"122","author":"XY Dong","year":"2008","unstructured":"Dong, X. Y. et al. Plac1 is a tumor\u2010specific antigen capable of eliciting spontaneous antibody responses in human cancer patients. International journal of cancer \n122, 2038\u20132043 (2008).","journal-title":"International journal of cancer"},{"key":"13682_CR28","volume":"12","author":"HS Kumara","year":"2012","unstructured":"Kumara, H. S. et al. MAGE-A3 is highly expressed in a subset of colorectal cancer patients. Cancer Immunity Archive \n12, 16 (2012).","journal-title":"Cancer Immunity Archive"},{"key":"13682_CR29","volume":"7","author":"WA Silva","year":"2007","unstructured":"Silva, W. A. et al. PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. Cancer Immunity Archive \n7, 18 (2007).","journal-title":"Cancer Immunity Archive"},{"key":"13682_CR30","volume":"9","author":"NE Tchabo","year":"2009","unstructured":"Tchabo, N. E. et al. Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. Cancer Immunity Archive \n9, 6 (2009).","journal-title":"Cancer Immunity Archive"},{"key":"13682_CR31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1145\/3386158","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians \n63, 11\u201330 (2013).","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"13682_CR32","first-page":"5","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA: a cancer journal for clinicians \n65, 5\u201329 (2015).","journal-title":"CA: a cancer journal for clinicians"},{"key":"13682_CR33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.15761\/ICST.1000192","volume":"3","author":"EJ Devor","year":"2016","unstructured":"Devor, E. J. Placenta-specific protein 1 (PLAC1) is a unique onco-fetal-placental protein and an underappreciated therapeutic target in cancer. Integr Cancer Sci Therap \n3, 479\u2013483 (2016).","journal-title":"Integr Cancer Sci Therap"},{"key":"13682_CR34","doi-asserted-by":"crossref","unstructured":"Khandelwal, A., Saber, H., Shapiro, M. A. & Zhao, H. In Antibody-Drug Conjugates and Immunotoxins 23\u201338 (Springer, 2013).","DOI":"10.1007\/978-1-4614-5456-4_2"},{"key":"13682_CR35","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1093\/jnci\/djt354","volume":"105","author":"A Azvolinsky","year":"2013","unstructured":"Azvolinsky, A. Conjugating antibodies to cytotoxic agents: getting the best of both worlds? Journal of the National Cancer Institute \n105, 1765\u20131766 (2013).","journal-title":"Journal of the National Cancer Institute"},{"key":"13682_CR36","doi-asserted-by":"crossref","unstructured":"Trail, P.A. In Antibody-Drug Conjugates and Immunotoxins 3\u201322 (Springer, 2013).","DOI":"10.1007\/978-1-4614-5456-4_1"},{"key":"13682_CR37","doi-asserted-by":"crossref","unstructured":"Widdison, W.C. & Chari, R.V. In Antibody-Drug Conjugates and Immunotoxins 93\u2013115 (Springer, 2013).","DOI":"10.1007\/978-1-4614-5456-4_6"},{"key":"13682_CR38","first-page":"1722","volume":"48","author":"Y-H Hsiang","year":"1988","unstructured":"Hsiang, Y.-H. & Liu, L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer research \n48, 1722\u20131726 (1988).","journal-title":"Cancer research"},{"key":"13682_CR39","first-page":"4187","volume":"51","author":"Y Kawato","year":"1991","unstructured":"Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H. & Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer research \n51, 4187\u20134191 (1991).","journal-title":"Cancer research"},{"key":"13682_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4155\/tde-2016-0002","volume":"7","author":"M Vankemmelbeke","year":"2016","unstructured":"Vankemmelbeke, M. & Durrant, L. Third-generation antibody drug conjugates for cancer therapy-a balancing act. Therapeutic delivery \n7, 141\u2013144 (2016).","journal-title":"Therapeutic delivery"},{"key":"13682_CR41","unstructured":"Hermanson, G. T. Bioconjugate techniques (Academic press, 2013)."},{"key":"13682_CR42","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.pep.2017.03.011","volume":"133","author":"M Nazari","year":"2017","unstructured":"Nazari, M. et al. Optimized protocol for soluble prokaryotic expression, purification and structural analysis of human placenta specific-1 (PLAC1). Protein Expression and Purification \n133, 139\u2013151 (2017).","journal-title":"Protein Expression and Purification"},{"key":"13682_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1600-0897.2010.00827.x","volume":"64","author":"A Moravej","year":"2010","unstructured":"Moravej, A. et al. Evaluation of thyroglobulin expression in murine reproductive organs during pregnancy. American Journal of Reproductive Immunology \n64, 97\u2013103 (2010).","journal-title":"American Journal of Reproductive Immunology"},{"key":"13682_CR44","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/963507","volume":"2014","author":"N Sepehri","year":"2014","unstructured":"Sepehri, N. et al. Human Serum Albumin Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN38) for Cancer Treatment. BioMed Research International \n2014, 11 (2014).","journal-title":"BioMed Research International"},{"key":"13682_CR45","unstructured":"Wilson, M. B. Nakane, P. P. & Wilson, M. Recent development in the periodate method of conjugating horseradish peroxidase(HRPO) to antibodies. Immunofluorescence and Related Staining Techniques. 215\u2013224 (1978)."},{"key":"13682_CR46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ab.2005.09.007","volume":"347","author":"K High","year":"2005","unstructured":"High, K., Meng, Y., Washabaugh, M. W. & Zhao, Q. Determination of picomolar equilibrium dissociation constants in solution by enzyme-linked immunosorbent assay with fluorescence detection. Analytical biochemistry \n347, 159\u2013161 (2005).","journal-title":"Analytical biochemistry"},{"key":"13682_CR47","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-14-2035","volume":"21","author":"S-F Yu","year":"2015","unstructured":"Yu, S.-F. et al. A novel anti-CD22 anthracycline-based antibody\u2013drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs. Clinical Cancer Research \n21, 3298\u20133306 (2015).","journal-title":"Clinical Cancer Research"}],"updated-by":[{"DOI":"10.1038\/s41598-025-00193-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13682-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13682-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13682-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T11:33:52Z","timestamp":1746617632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13682-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,17]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["13682"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-13682-9","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-025-00193-1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,17]]},"assertion":[{"value":"5 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-025-00193-1","URL":"https:\/\/doi.org\/10.1038\/s41598-025-00193-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13373"}}